TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Boehringer Ingelheim and 3T Biosciences Embark on a Second Collaboration to Advance the Development of Next-generation Cancer Immunotherapies

Friday, January 05, 2024

Boehringer Ingelheim and 3T Biosciences have recently announced a renewed strategic collaboration and licensing agreement focused on advancing cancer immunotherapies. Despite the progress in cancer treatment with immunotherapies, sustained remission occurs in only 15-20% of cases. Boehringer Ingelheim aims to significantly improve this rate by leveraging various immuno-oncology platforms, including T-Cell Engagers (TcEs), oncolytic viruses, and cancer vaccines.

This partnership builds upon the success of the initial collaboration between the two companies announced last year. Boehringer Ingelheim plans to combine 3T's 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with its own commitment to developing pioneering immuno-oncology treatments that enhance the immune system's ability to target and eliminate tumors.

Lamine Mbow, Global Head of Cancer Immunology and Immune Modulation at Boehringer Ingelheim, expressed confidence in expanding and accelerating their pipeline of T-cell-based anti-cancer therapies based on the initial success with 3T. Stefan J. Scherer, President and CEO of 3T Biosciences, highlighted the higher degree of validation for their 3T-TRACE discovery platform achieved through the collaboration.

Under the agreement, Boehringer Ingelheim will supply patient-derived T-cell receptor (TCR) data to support 3T's target discovery efforts. 3T will receive an upfront payment, research and development support, and is eligible for various milestones totaling $538.5 million, along with royalties on future product sales. Boehringer Ingelheim, in turn, may receive royalties on future product sales by 3T Biosciences resulting from the collaboration.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit